Navigation Links
In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
Date:7/15/2013

BURLINGTON, Mass., July 15, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European oncologists' prescribing decisions for second-line metastatic colorectal cancer. Clinical data and the opinions of interviewed thought leaders, however, indicate that current and emerging therapies have no advantage over the sales-leader bevacizumab (Genentech/Roche/Chugai's Avastin)/FOLFIRI (5-fluorouracil, leucovorin and irinotecan) on overall survival, one of the greatest unmet needs in second-line metastatic colorectal cancer. However, opinion leaders express optimism that clinical trial data could show that the mechanism of action of Eli Lilly/ImClone's ramucirumab could confer a benefit on progression-free survival.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Decision Base 2013 report entitled As the Second-Line Treatment Setting for Colorectal Cancer Becomes More Crowded, How Will Oncologists and Payers Differentiate Among New Therapies?  finds that surveyed U.S. oncologists would prescribe ramucirumab, in combination with FOLFIRI, to a median of 20 percent of their second-line drug-treated, metastatic colorectal cancer patients. This modest patient share demonstrates the struggle that a new agent will face penetrating the familiarity of Avastin, as well as strong competition from aflibercept (Sanofi/Regeneron's Zaltrap) and regorafenib (Bayer Healthcare's Stivarga), the latter of which is currently used primarily in later lines of treatment.

The findings also reveal that the safety and tolerability of second-line therapies for metastatic colorectal cancer are another important consideration in oncologists' prescribing decisions, as the incidence of colorectal cancer increases with age and, as a result, therapies in this setting have a great impact on the quality of life in an elderly population.  

The report also finds that surveyed managed care organization (MCO) pharmacy directors are receptive to novel therapies that offer an improvement in median overall survival over currently available therapies, but while some emerging therapies hold promise, they are unlikely to match payers' requirements for widespread inclusion on their formularies.

"Avastin in combination with FOLFIRI is currently the most widely used regimen for the second-line treatment of metastatic colorectal cancer," said Decision Resources Business Insights Analyst Dana Gheorghe, Ph.D. "An emerging therapy like ramucirumab will find it difficult to penetrate the already crowded second-line market, given physicians' familiarity with Avastin. However, if ramucirumab can show competitive advantages in efficacy, and safety in Phase III trials, we believe it has the potential to compete strongly following its anticipated launch in 2015."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelerate Diagnostics Announces Final Terms of Rights Offering
2. Cancer Vaccine Partnering Terms and Agreements
3. Medstrat Posts Documents Confirming Terms Of Dismissal Of Merges Lawsuit
4. On-Demand Reports on Partnering Terms in Healthcare & Pharma Sectors: New Market Research at ReportsnReports.com
5. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
6. Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinsons Blood Test Joint Venture
7. Sonendo Agrees To Terms For Up To $20 Million In Financing
8. Vaccine Partnering Terms and Agreements
9. Managing Healthcare Reform through Effective Engagement with the Government Ecosystem
10. Side Effects Limit Prescription Drug Compliance
11. CHPA Applauds Pennsylvanias Adoption of Real-Time, Stop-Sale Technology, An Effective Tool in the Fight Against Methamphetamine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):